Webinar available to view on demand. Thursday 27 September 2018. In this webinar, learn about utilizing xMAP® technology coupled with machine learning algorithms to detect polyps and early-stage colorectal cancer
Time-of-flight secondary ion mass spectrometry utilized in novel technique to map tumor cell signaling
A team from the University of Washington (WA, USA) has demonstrated the use of time-of-flight secondary ion mass spectrometry for mapping tumor cell signals in pancreatic cancer mouse models.
Current methods for the treatment of cancer include radiation, chemotherapy and surgical intervention, but alternative treatment modalities exist should these traditional methods prove unsuccessful. In this blog post, Dominic Warrino (KCAS; KS, USA), shares his insights into immuno-oncology, and discusses two case studies utilizing antibody drug conjugates and cellular therapies.
Read time: 1:30 mins
Researchers at Cold Spring Harbor Laboratory (NY, USA) have developed a novel method to identify biomarkers for the most common form of liver cancer, hepatocellular carcinoma.
Researchers from King Saud University (Riyadh, Saudi Arabia) have developed a new ELISA technique, with increased sensitivity and selectivity, for the simple monitoring of bevacizumab levels in blood plasma.
In this month long feature, we bring you a collection of content focusing on the ‘hot topic’ of immuno-oncology.
Find out what Future Science Group are doing to mark World Cancer Day 2018
Issue 20 of Bioanalysis volume 9 is now available, including an editorial surrounding the factors which may impact PK measurements of antibody therapeutics alongside the latest methodologies, research articles and discussions of current bioanalytical challenges. Find out more about the issue here, or on the Bioanalysis webpage.
Three single-nucleotide polymorphisms have been identified as viable candidates as biomarkers for the personalized monitoring and treatment of lung cancers.
Innovate UK award BioMoti, Pharmidex and Queen Mary University of London Biomedical Catalyst grant of £662,222
BioMoti, Pharmidex and Queen Mary University of London awarded grant to support preclinical studies of new therapeutic approaches for hard to treat tumors.